Senescent cells - what zombie cells do to your tissues
Senescent cells — what zombie cells do to your tissues
Cellular senescence is the state in which a cell permanently exits the cell cycle — stops dividing — in response to damage, stress or developmental signals. In principle this is a protective mechanism: a damaged cell that cannot replicate its errors. In practice, senescent cells do not simply fall silent. They remain metabolically active, secreting a pro-inflammatory cascade of cytokines, chemokines and proteases that impairs surrounding tissue, recruits immune cells and drives the chronic inflammation of ageing. They have been called zombie cells for good reason — they are functionally dead but refuse to leave.
The SASP — the inflammatory signal of senescent cells
The senescence-associated secretory phenotype (SASP) is the defining characteristic of senescent cells. Rather than being inert, senescent cells actively secrete elevated levels of pro-inflammatory cytokines (IL-1alpha, IL-6, IL-8), chemokines, growth factors and matrix metalloproteinases (MMPs). This secretome has paracrine effects — it induces senescence in neighbouring healthy cells, recruits inflammatory immune cells to the tissue, degrades the extracellular matrix and disrupts normal tissue architecture and function.
The SASP is directly relevant to virtually every chronic age-related disease. IL-6 and IL-1 secreted by senescent cells drive the chronic low-grade inflammation of inflammageing. MMPs secreted by senescent fibroblasts degrade collagen and elastin in skin, cartilage and blood vessel walls. SASP chemokines create the inflammatory microenvironment that promotes tumour progression in pre-cancerous tissues. A single senescent cell can exert SASP effects across hundreds of surrounding cells — explaining why even modest accumulations produce significant tissue-level consequences.
Why senescent cells accumulate with age
Cells enter senescence in response to telomere shortening (replicative senescence after sufficient cell divisions), genotoxic stress (DNA damage from UV radiation, oxidative stress or oncogenic signals), metabolic stress and developmental signals. In youth, the immune system — particularly NK cells and macrophages — efficiently clears senescent cells. With age, immune surveillance declines and senescent cell clearance becomes less efficient, allowing senescent cells to accumulate progressively in tissues throughout the body.
A 2016 landmark Nature Medicine study by Baker et al. demonstrated that selective removal of p16Ink4a-positive senescent cells in progeroid mice delayed the onset of age-related pathology, preserved tissue function and extended median lifespan by 25%. This established clearance of senescent cells as causally beneficial — not merely correlative — for longevity, catalysing the field of senolytic drug development.
What senescent cells do to tissues
The tissue-specific consequences of senescent cell accumulation are extensive and mechanistically well-characterised. In adipose tissue, senescent cells drive insulin resistance through inflammatory cytokine signalling. In the liver, senescent hepatic stellate cells promote fibrosis. In vascular endothelium, senescent cells reduce nitric oxide availability, increasing arterial stiffness and cardiovascular risk. In the brain, senescent microglia and astrocytes contribute to neuroinflammation associated with cognitive decline. In joints, senescent chondrocytes impair cartilage maintenance and drive osteoarthritis progression.
Senolytics — clearing senescent cells
Senolytics are compounds that selectively kill senescent cells by targeting the anti-apoptotic pathways that senescent cells depend on for survival — specifically the BCL-2 family proteins, PI3K-delta and HIF-1alpha. The Mayo Clinic has led the most significant human senolytic trials to date, using the dasatinib-quercetin (D+Q) combination that was identified in 2015 by Kirkland et al. as the first senolytic regimen with human clinical evidence.
A 2019 Mayo Clinic pilot trial in idiopathic pulmonary fibrosis patients confirmed that D+Q reduced senescent cell burden (assessed by p16 and p21 gene expression), improved physical function and reduced inflammatory markers over three weeks of intermittent dosing. A 2020 Mayo Clinic trial in diabetic kidney disease confirmed similar reductions in senescent cell markers alongside improvements in physical function. These trials established proof-of-concept that senolytic intervention is feasible and beneficial in human ageing-related diseases.
Fisetin and quercetin — the naturopathic senolytics
Fisetin (3,3',4',5,7-pentahydroxyflavone) is a naturally occurring flavonoid found in strawberries, apples, persimmons and onions that was identified as a potent senolytic in a 2018 EBioMedicine study by the Mayo Clinic group. At doses of 100mg/kg in aged mice, fisetin reduced senescent cell burden by 25-50%, reduced inflammatory markers and extended remaining lifespan by 10%. A 2023 human pilot trial published in EBioMedicine confirmed that fisetin at 20mg/kg for two consecutive days per month reduced inflammatory markers and senescent T cell populations in older adults.
Quercetin — found in onions, capers, apples and berries — was the natural compound used alongside dasatinib in the original Mayo Clinic senolytic protocol and has independently demonstrated senolytic activity in multiple cell and animal studies. Quercetin is also a CD38 inhibitor (relevant to NAD+ preservation) and an anti-inflammatory flavonoid, making it one of the most multi-mechanistic natural longevity compounds currently in evidence.
Dietary senolytics and senescence prevention
Prevention of senescent cell accumulation is more tractable than clearance. The dietary patterns associated with reduced senescent cell burden include high polyphenol intake (particularly flavonoids, anthocyanins and stilbenes), caloric moderation, adequate protein with resistance training to maintain muscle quality, and minimisation of the genotoxic and oxidative stressors — smoking, alcohol, ultra-processed food, excess sun exposure — that drive cellular senescence.
Address senescent cell accumulation clinically
The Longevity Blueprint includes inflammatory marker assessment and a personalised protocol addressing senescence-related biological ageing. Every enquiry begins with a complimentary Discovery Call.
Book a complimentary Discovery Call View The Longevity BlueprintReferences
- Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nature Reviews Molecular Cell Biology. 2007;8(9):729-740.
- Baker DJ, Childs BG, Durik M, et al. Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. Nature. 2016;530(7589):184-189.
- Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644-658.
- Kirkland JL, Tchkonia T, Zhu Y, Niedernhofer LJ, Robbins PD. The clinical potential of senolytic drugs. Journal of the American Geriatrics Society. 2017;65(10):2297-2301.
- Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 2019;40:554-563.
- Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28.
- Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annual Review of Pathology. 2010;5:99-118.
- Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nature Medicine. 2018;24(8):1246-1256.
- Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446-456.
- van Deursen JM. The role of senescent cells in ageing. Nature. 2014;509(7501):439-446.
Longevity Medicine Series — all articles
NAD+ Biological age Autophagy Muscle & longevity Senescent cells Inflammageing Brain health Red light therapy Peptides GLP-1 & berberine Post-pill recovery Gut & longevity Mitochondria Sleep & longevity Testosterone & women Methylation & MTHFR Omega-3 Fasting & TRE Microbiome & longevity Cardiovascular longevity Perimenopause & menopause Vitamin D & longevity Epigenetic clocks Longevity consultation